Hyperkalemia, a life-threatening condition, can occur due to various medication use, kidney dysfunction, or alternative sources of electrolyte disparity. The cases of hyperkalemia have been rising with the increasing prevalence of cancer and gastrointestinal disease. Hyperkalemia has been reported in less than 5% of the general population worldwide. The incidence and prevalence of hyperkalemia have been estimated to be 2-3% in the general population and 1% to 10% among hospitalized patients. Also, people with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines called renin-angiotensin-aldosterone system inhibitors (RAASi) have an estimated 2 to 3 times higher risk for hyperkalemia.
Scope of the Report
Hyperkalemia, defined as a serum potassium concentration greater than 5.0–5.3 mEq/L, which is found to be rare in a general population of healthy individuals. The report covers the market trends of the medication used for acute and chronic hyperkalemia.
Key Market Trends
Chronic hyperkalemia dominates the Global Hyperkalemia Treatment Market
Chronic hyperkalemia is usually related to impaired renal excretion. Chronic hyperkalemia is usually asymptomatic, hence the treatment goals include prevention of generalized symptoms, cardiac dysrhythmias, and death. Treatment of chronic hyperkalemia includes diuretics, bicarbonate salts, dietary restriction, potassium binders, and dialysis. Also, chronic hyperkalemia is one of the major complications of chronic kidney disease (CKD) that occurs frequently and requires careful management by the nephrologist. This segment is projected to lead the global market throughout the forecast period.
North America Dominates the Global Hyperkalemia Treatment Market
North America holds a leading position in the hyperkalemia treatment market owing to advanced medical technology and rising aging populations which are likely to contribute to increased prevalence of heart failure and chronic kidney disease and accordingly a larger pool of patients at risk for hyperkalemia. An estimated 3.7 million US adults had hyperkalemia in the year 2014, and this prevalence rate has been increasing since 2010. In patients with CKD and/or heart failure, the annual prevalence of hyperkalemia was 6.35% in 2014, and about half of all patients with hyperkalemia have either CKD and/or heart failure. Easy access to medication, raising awareness, and favorable reimbursement are the key factors driving the market in this region.
The hyperkalemia market is consolidated, dominated by a few players. The hyperkalemia market underwent extensive changes with the introduction of Veltassa at the beginning of 2016 which represented the first new therapy for the treatment of hyperkalemia in over 50 years. Few key market players in the market are AstraZeneca Plc, Ardelyx, Vifor Pharma Management Ltd, Sanofi S.A., and Perrigo Company plc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support